Traders Purchase High Volume of Gossamer Bio Call Options (NASDAQ:GOSS)

Gossamer Bio, Inc. (NASDAQ:GOSS) was the recipient of unusually large options trading activity on Wednesday. Traders purchased 35,941 call options on the stock. This represents an increase of approximately 964% compared to the typical volume of 3,379 call options.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on GOSS shares. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a report on Wednesday, October 8th. Wall Street Zen raised shares of Gossamer Bio from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Gossamer Bio in a research note on Thursday, September 11th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.50.

Institutional Investors Weigh In On Gossamer Bio

Several large investors have recently added to or reduced their stakes in GOSS. Bank of America Corp DE raised its stake in Gossamer Bio by 107.2% in the 4th quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock valued at $77,000 after acquiring an additional 43,866 shares during the period. Invesco Ltd. purchased a new position in shares of Gossamer Bio in the first quarter worth about $48,000. Cubist Systematic Strategies LLC bought a new stake in shares of Gossamer Bio in the first quarter valued at approximately $213,000. Goldman Sachs Group Inc. lifted its stake in shares of Gossamer Bio by 720.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after buying an additional 825,047 shares in the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Gossamer Bio by 5,250.1% during the 1st quarter. Jane Street Group LLC now owns 683,423 shares of the company’s stock valued at $752,000 after buying an additional 670,649 shares in the last quarter. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Stock Up 3.7%

Gossamer Bio stock opened at $2.50 on Friday. The firm has a 50 day moving average price of $3.07 and a 200-day moving average price of $2.49. Gossamer Bio has a twelve month low of $0.76 and a twelve month high of $3.87. The company has a market capitalization of $578.65 million, a P/E ratio of -3.62 and a beta of 1.92.

Gossamer Bio (NASDAQ:GOSS) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Gossamer Bio had a negative return on equity of 1,774.72% and a negative net margin of 354.50%.The company had revenue of $13.29 million during the quarter, compared to the consensus estimate of $6.32 million. Equities analysts expect that Gossamer Bio will post -0.28 EPS for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.